Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
Comprehensive review identifies cannabinoids among local therapeutic options for neurocutaneous dysesthesia, a challenging nerve-related skin condition.
This review establishes that neurocutaneous dysesthesia represents a distinct clinical entity requiring targeted local therapy when systemic treatments are unsuitable. The inclusion of cannabinoids alongside established agents like capsaicin and topical anesthetics suggests growing recognition of cannabinoid utility in peripheral neuropathic conditions.
Neurocutaneous dysesthesia often leaves patients with limited treatment options, particularly when systemic medications are contraindicated. Having a comprehensive framework of local therapies, including cannabinoids, provides clinicians with evidence-based alternatives for this challenging condition.
| Study Type | Narrative Review |
| Population | Patients with neurocutaneous dysesthesia (abnormal skin sensations without underlying skin pathology) |
| Intervention | Local therapeutic modalities including cannabinoids among multiple topical agents |
| Comparator | Comparative overview of various local treatment approaches |
| Primary Outcome | Review of mechanisms of action and clinical applications of local treatments |
| Key Finding | Multiple local therapeutic options identified including cannabinoids as potential treatment for nerve-related skin symptoms |
| Journal | The Journal of dermatological treatment |
| Year | 2024 |
Local cannabinoid therapy represents a legitimate treatment consideration for neurocutaneous dysesthesia, positioned alongside established topical agents in the therapeutic armamentarium. This review validates the clinical rationale for topical cannabinoid use in nerve-related skin symptoms.
The abstract does not provide specific efficacy data, dosing protocols, or comparative effectiveness between cannabinoids and other local treatments. No information is given about which specific cannabinoids were reviewed or their relative clinical performance.
As a narrative review, this does not constitute primary evidence for cannabinoid efficacy. The quality and quantity of underlying studies supporting each treatment modality, including cannabinoids, cannot be assessed from this abstract alone.
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →This review legitimizes cannabinoids as a consideration for topical neuropathic skin conditions but represents expert opinion synthesis rather than primary efficacy evidence. Clinicians should view this as a framework for treatment approaches rather than definitive guidance.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
